MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Castle Biosciences EV/EBITDA Ratio 2011-2026 | CSTL
Annual EV/EBITDA Ratio Castle Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -21.2 | -142 | 24 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24 | -142 | -46.4 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Lantheus Holdings
LNTH
|
-187 | $ 74.6 | -1.49 % | $ 5.03 B |  USA |
 |
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
26.4 | $ 9.28 | 3.11 % | $ 618 M | USA |
|
Biodesix
BDSX
|
-4.25 | $ 15.5 | 5.51 % | $ 2.01 B | USA |
 |
Medpace Holdings
MEDP
|
30.7 | $ 465.57 | 1.89 % | $ 13.4 B | USA |
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
-17.2 | $ 4.7 | 0.86 % | $ 435 M | USA |
 |
National Research Corporation
NRC
|
21 | $ 17.38 | -0.77 % | $ 389 M | USA |
 |
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
3.62 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
-23.8 | $ 1.39 | - | $ 417 M | USA |
 |
Charles River Laboratories International
CRL
|
22 | $ 160.55 | 1.56 % | $ 7.96 B | USA |
 |
IQVIA Holdings
IQV
|
24.1 | $ 168.36 | 0.81 % | $ 28.9 B | USA |
 |
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
-10.7 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-7.71 | $ 1.21 | -17.22 % | $ 6.59 M | USA |
 |
Mettler-Toledo International
MTD
|
827 | $ 1 268.55 | 2.27 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
-6.02 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
70.5 | $ 126.25 | 1.99 % | $ 20.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
-1.8 | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
-7.07 | $ 7.73 | 1.58 % | $ 458 M | USA |
 |
RadNet
RDNT
|
17.6 | $ 59.61 | -3.45 % | $ 4.48 B | USA |
 |
Celcuity
CELC
|
-2.38 | $ 101.54 | -4.89 % | $ 4.01 B | USA |
 |
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 266.82 | 0.88 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | Israel |
 |
Senseonics Holdings
SENS
|
-13.8 | $ 6.74 | 1.81 % | $ 281 M | USA |
 |
Sotera Health Company
SHC
|
24.8 | $ 13.89 | 0.07 % | $ 3.94 B | USA |
 |
ENDRA Life Sciences
NDRA
|
0.831 | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
-33.5 | $ 7.94 | -1.98 % | $ 1.02 B | USA |
 |
Soleno Therapeutics
SLNO
|
0.12 | $ 30.98 | -2.33 % | $ 1.57 B | USA |
 |
Natera
NTRA
|
-19.5 | $ 197.02 | -1.53 % | $ 19.4 B | USA |
 |
CareDx, Inc
CDNA
|
-100 | $ 17.95 | 2.22 % | $ 957 M | USA |
 |
Neuronetics
STIM
|
-1.45 | $ 1.49 | -6.88 % | $ 98.3 M | USA |
 |
OPKO Health
OPK
|
25.9 | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
DarioHealth Corp.
DRIO
|
-1.05 | $ 7.99 | 6.53 % | $ 31.8 M | Israel |
 |
DexCom
DXCM
|
39.5 | $ 66.84 | 1.36 % | $ 26.1 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-20.8 | $ 104.91 | - | $ 19.8 B | USA |